ATE58059T1 - Arylcyclobutylalkylamin-derivat zur behandlung von morbus parkinson. - Google Patents

Arylcyclobutylalkylamin-derivat zur behandlung von morbus parkinson.

Info

Publication number
ATE58059T1
ATE58059T1 AT88301625T AT88301625T ATE58059T1 AT E58059 T1 ATE58059 T1 AT E58059T1 AT 88301625 T AT88301625 T AT 88301625T AT 88301625 T AT88301625 T AT 88301625T AT E58059 T1 ATE58059 T1 AT E58059T1
Authority
AT
Austria
Prior art keywords
formula
parkinson
optionally substituted
disease
treatment
Prior art date
Application number
AT88301625T
Other languages
English (en)
Inventor
John Andrew Rees
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boots Co Plc filed Critical Boots Co Plc
Application granted granted Critical
Publication of ATE58059T1 publication Critical patent/ATE58059T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT88301625T 1987-02-28 1988-02-25 Arylcyclobutylalkylamin-derivat zur behandlung von morbus parkinson. ATE58059T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878704777A GB8704777D0 (en) 1987-02-28 1987-02-28 Medical treatment
EP88301625A EP0282206B1 (de) 1987-02-28 1988-02-25 Arylcyclobutylalkylamin-Derivat zur Behandlung von Morbus Parkinson

Publications (1)

Publication Number Publication Date
ATE58059T1 true ATE58059T1 (de) 1990-11-15

Family

ID=10613147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88301625T ATE58059T1 (de) 1987-02-28 1988-02-25 Arylcyclobutylalkylamin-derivat zur behandlung von morbus parkinson.

Country Status (9)

Country Link
US (2) US4816488A (de)
EP (2) EP0303677A1 (de)
JP (1) JPH0643299B2 (de)
AT (1) ATE58059T1 (de)
DE (1) DE3860960D1 (de)
GB (1) GB8704777D0 (de)
GR (1) GR3001395T3 (de)
WO (1) WO1988006444A1 (de)
ZA (1) ZA881417B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
GB9309749D0 (en) * 1993-05-12 1993-06-23 Boots Co Plc Therapeutic agents
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
WO2000056310A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
WO2000056319A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
US6433020B1 (en) 1999-03-19 2002-08-13 Knoll Pharmaceutical Company Treatment of cardiovascular disease
US6403650B1 (en) 1999-03-19 2002-06-11 Knoll Pharmaceutical Company Treatment of pulmonary hypertension
WO2000056311A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Control of metabolism
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
GB9915617D0 (en) 1999-07-05 1999-09-01 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
EP1567180A4 (de) * 2002-06-04 2010-03-10 Avicena Group Inc Verfahren zur behandlung von kognitiver dysfunktion durch modulierung des energiestoffwechsels im gehirn
CN101098850B (zh) 2005-01-06 2010-09-15 Cj第一制糖株式会社 西布曲明的无机酸盐

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound

Also Published As

Publication number Publication date
GB8704777D0 (en) 1987-04-01
US4871774A (en) 1989-10-03
ZA881417B (en) 1988-09-02
DE3860960D1 (de) 1990-12-13
EP0303677A1 (de) 1989-02-22
JPH01500356A (ja) 1989-02-09
WO1988006444A1 (en) 1988-09-07
EP0282206B1 (de) 1990-11-07
JPH0643299B2 (ja) 1994-06-08
GR3001395T3 (en) 1992-09-11
EP0282206A1 (de) 1988-09-14
US4816488A (en) 1989-03-28

Similar Documents

Publication Publication Date Title
ATE58059T1 (de) Arylcyclobutylalkylamin-derivat zur behandlung von morbus parkinson.
NO892952D0 (no) 4-oksokinolin-3-karboksylsyrederivater, fremgangsmaate tilfremstilling av og anvendelse av samme.
DK20388D0 (da) Hidtil ukendt behandling
PE20010634A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
KR870001167A (ko) 5-이미다졸카르복시산 유도체의 제조방법
DK0694545T3 (da) Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
NO924783D0 (no) Terapeutiske midler
NO152047C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksom 5-(paradeuterofenyl)-5-fenylhydantoin
HU911992D0 (en) 2-(amino-alkyl)-5-(aryl-alkyl)-1,3-dioxanes, and process for the production of the medical preparations containing them
ATE137759T1 (de) S&#39;-adenosyl-methionin-decarboxylase-inhibitoren
GB1009797A (en) Pyrrole derivatives
HK1030419A1 (en) Stereoisomeric indole compounds, process for the preparation of the same, and use thereof.
DE3460841D1 (en) Mercaptoacetic acid and 3-mercaptopropionic acid amide derivatives for use in treatment of a human or animal body, some new derivatives and pharmaceutical compositions containing them
DE69405999T2 (de) Pharmazeutisch wirksame enantiomere
GB2006196A (en) Phenylacetamides with analgesic activity
GB1078975A (en) Improvements in or relating to n-substituted piperazino-alkoxy-acetophenone derivatives
ATE44741T1 (de) 2-(n-substituierte guanidino)-4heteroarylthiazole als mittel gegen geschwuere.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time